Evgeunia Bhurtel on Muck Rack

Evgeunia Bhurtel

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Evgeunia

Contact Evgeunia, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)—real world experience from the US multiple myeloma immunotherapy consortium

|
By CINDY varga, Myra Robinson, James Davis, Hamza Hashmi, Thomas Martin, Anupama Kumar, Douglas Sborov, Charlotte Wagner, Doris Hansen, Omar Castaneda Puglianini, Leyla O. Shune, Aimaz Afrough, Larry D. Jr, Binod Dhakal, Megan Herr Verified, Shambavi Richard, Alex Lieberman-Cribbin, Daniel W. Sherbenou, Peter Forsberg, Sneha Purvey, Jack Khouri, Yi Lin, Surbhi Sidana, Shonali Midha, Christopher J. Ferreri, Evgeunia Bhurtel, Mehmet Kocoglu
| Nature Verified
Abstract Prolonged cytopenias are a well-recognized complication following CAR-T therapy. Autologous SCB offers a potential strategy to promote fast hematologic recovery. We conducted a retrospective multi-institutional comparing outcomes of SCB versus supportive care alone in patients with prolonged cytopenias after CAR-T infusion. Patients were included if they received SCB within 1 year following commercial CAR-T between 6/2021 and 3/2024.
Open in Who Shared Issue with article?
See all 1 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified